Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cordance's Blood-Brain Barrier Opening Device Wins FDA Breakthrough Nod - Medical Product Outsourcing
OEM News

Cordance’s Blood-Brain Barrier Opening Device Wins FDA Breakthrough Nod

NeuroAccess uses focused ultrasound with microbubbles to safely and temporarily open the BBB for liquid biopsies of brain tumors.

Cordance Medical, a company focused on opening the blood-brain barrier (BBB) to facilitate liquid biopsy, has received breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its NeuroAccess device.
 
NeuroAccess, which is designed for patients 22 and up with known or suspected brain tumors, helps non-invasively elevate cell-free DNA (cfDNA) analytes in blood circulation. The procedure is called SonoBiopsy and the company says it boosts existing oncology liquid biopsy assays.
 
The technology uses focused ultrasound combined with microbubbles to safely and temporarily open the BBB. The portable NeuroAccess device aims to bring SonoBiopsy broadly across community clinics and hospitals.
 
Earlier this year, pioneering studies at Washington University in St. Louis demonstrated a SonoBiopsy procedure in brain tumor patients was safe and feasible to facilitate liquid biopsies. Cordance Medical has partnered with SonoBiopsy investigators Dr. Eric Leuthardt and Dr. Hong Chen and recently announced licensing of intellectual property with Washington University in St Louis.
 
Cordance’s technology hopes to revolutionize both liquid biopsy and drug delivery techniques for glioblastoma multiforme (GBM), brain metastasis, Alzheimer’s, Parkinson’s, and other neurologic diseases.
 
“This Breakthrough Device Designation from the FDA is a pivotal milestone for Cordance Medical and for patients requiring more efficacious diagnostic solutions,” Cordance Medical CEO Ryan Dittamore told the press. “We are keen to continue our clinical trials and to collaborate closely with the FDA to bring this groundbreaking technology to market.”

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters